Cognitive Functioning and Acute Sedative Effects of Risperidone and Quetiapine in Patients With Stable Bipolar I Disorder: A Randomized, Double-Blind, Crossover Study
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Antipsychotic medications differ in their sedative potential, which can affect cognitive performance. The primary objective of this double-blind study was to compare the effects of treatment initiation with risperidone and quetiapine on cognitive function in subjects with stable bipolar disorder. METHOD: Subjects had a DSM-IV diagnosis of bipolar I disorder in partial or full remission and a Young Mania Rating Scale score <or= 8 at screening. Subjects were randomly assigned to 1 of 2 treatment sequences: risperidone-quetiapine or quetiapine-risperidone. Subjects in the risperidone-quetiapine sequence received 2 mg of risperidone with dinner and placebo with breakfast during period 1 and 100 mg of quetiapine with dinner and 100 mg with breakfast during period 2. Subjects in the quetiapine-risperidone sequence received the same treatments in reverse order. The 2 treatment periods were separated by a 6- to 14-day washout period. Cognitive function, including attention, working memory, declarative memory, processing speed, and executive functions, was measured before and after dosing. The Visual Analog Scale for Fatigue was also completed. The primary endpoint was a neurocognitive composite score (NCS). The study was conducted from November 2004 through August 2005. RESULTS: Thirty subjects were randomly assigned; 28 took all doses of study medication and completed a baseline and at least 1 postbase-line assessment in each treatment. On the NCS, significantly better overall cognitive function was seen after risperidone than after quetiapine at each time point after dosing. Subjects performed significantly better after risperidone than after quetiapine (p < .05) on 9 of the 18 individual cognitive outcome measures and significantly better after quetiapine than after risperidone on 1 measure. Sleeping or the need for sleep during the test days was reported in significantly more patients after receiving quetiapine than risperidone. CONCLUSIONS: The results indicate that initiation of quetiapine treatment was associated with more immediate adverse cognitive effects and increased somnolence than risperidone treatment. CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov identifier NCT00097032.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the atypical antipsychotic risperidone, which produces dopaminergic, noradrenergic, and serotonergic antagonism, improves working memory in schizophrenia and bipolar patients (Harvey et al 2007, Harvey et al 2005).”
From Prefrontal cortex executive processes affected by stress in health and disease (2018) · cites this paper as Harvey et al 2007, Harvey et al 2005
Citations
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744
The mini international neuropsychiatric interview
Lecrubier, Y., Sheehan, D., Hergueta, T., & Weiller, E. (1998) · European Psychiatry · doi:10.1016/s0924-9338(99)80239-9 · Cited by 5,872
Norman, G. R., Sloan, J. A., & Wyrwich, K. W. (2003) · Medical Care · doi:10.1097/01.mlr.0000062554.74615.4c · Cited by 4,700
A continuous performance test of brain damage
Rosvold, H. E., Mirsky, A. F., Sarason, I., Bransome, E. D., & Beck, L. H. (1956) · Journal of Consulting Psychology · doi:10.1037/h0043220 · Cited by 2,261
Identification of separable cognitive factors in schizophrenia
Nuechterlein, K. H., Barch, D. M., Gold, J. M., Goldberg, T. E., Green, M. F., & Heaton, R. K. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.09.007 · Cited by 1,304
Validity and reliability of a scale to assess fatigue
Lee, K. A., Hicks, G., & Nino-Murcia, G. (1991) · Psychiatry Research · doi:10.1016/0165-1781(91)90027-m · Cited by 1,261 · cited 2×
“The scale has been validated in a study of fatigue and sleep disorders.(39) The VAS-F is a paper and pencil test that comprises 18 individual visual analog scales that evaluate different aspects of fatigue (13 items) and vigor (5 items).”
MethodAssessing Adolescent and Adult Intelligence
Kaufman, A. S. (1990) · Medical Entomology and Zoology · Cited by 1,207
Principles of behavioral neurology
Mesulam, M. M. (1985) · Davis eBooks · Cited by 991
The measurement of adult intelligence (3rd ed.).
Wechsler, D. (1946) · Williams & Wilkins eBooks · doi:10.1037/11329-000 · Cited by 824
Cited by
Evolution of neuropsychological dysfunction during the course of schizophrenia and bipolar disorder
Lewandowski, K. E., Cohen, B. M., & Öngur, D. (2011) · Psychological Medicine · doi:10.1017/s0033291710001042 · Cited by 336
“Cognitive side-effects may occur as a direct consequence of the drug’s mechanism of action or indirectly through side-effects such as sedation (e.g. Harvey et al. 2007).”
BackgroundGoodwin, G. M., Martinez-Aran, A., Glahn, D. C., & Vieta, E. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.07.005 · Cited by 180
“Similar studies are now needed in patients with BD, to understand if cognitive benefits, with improvements in social, occupational, and interpersonal function are also attainable using the atypical antipsychotics (Reinares et al., 2000; Harvey et al., 2007).”
BackgroundPrefrontal cortex executive processes affected by stress in health and disease
Girotti, M., Adler, S. M., Bulin, S. E., Fucich, E. A., Paredes, D., & Morilak, D. A. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.07.004 · Cited by 176
Cognitive impairment in bipolar disorder and schizophrenia: a systematic review
Vöhringer, P. A., Barroilhet, S. A., Amerio, A., Reale, M. L., Alvear, K., Vergne, D., & Ghaemi, S. N. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00087 · Cited by 165
Neuroprogression and Cognitive Functioning in Bipolar Disorder: A Systematic Review
Cardoso, T., Bauer, I. E., Meyer, T. D., Kapczinski, F. P., & Soares, J. C. (2015) · Current Psychiatry Reports · doi:10.1007/s11920-015-0605-x · Cited by 175
Pharmacological approaches in bipolar disorders and the impact on cognition: a critical overview
Dias, V. V., Balanzá‐Martinez, V., Soeiro‐de‐Souza, M. G., Moreno, R. A., Figueira, M. L., Machado‐Vieira, R., & Vieta, E. (2012) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2012.01910.x · Cited by 146
“Olanzapine has been shown to improve abnormal though processes in manic patients (130, 131) and has been shown to up-regulate Bcl-2 and CREB, which may underlie its neuroplastic actions in subjects with BD (132).”
BackgroundNeurocognition in bipolar disorders—A closer look at comorbidities and medications
Balanzá‐Martínez, V., Selva, G., Martínez‐Arán, A., Prickaerts, J., Salazar, J., González-Pinto, A. M., Vieta, E., & Tabarés‐Seisdedos, R. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.10.018 · Cited by 144
“The only randomized, double-blind study to date (Harvey et al., 2007) compared the acute neurocognitive effects of low-dosed risperidone and quetiapine in clinically stable BD patients.”
BackgroundHains, A. B., & Arnsten, A. F. T. (2008) · Learning & Memory · doi:10.1101/lm.921708 · Cited by 127
Chengappa, K. N. R., Bowie, C. R., Schlicht, P. J., Fleet, D., Brar, J. S., & Jindal, R. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08413 · Cited by 120
Gäebel, W., Schreiner, A., Bergmans, P., de Arce, R., Rouillon, F., Cordes, J., Eriksson, L., & Smeraldi, E. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.111 · Cited by 119
“%) similar to previous observations (Harvey et al, 2007; Said et al, 2008).”
Effects of atypical antipsychotics on neurocognition in euthymic bipolar patients
Torrent, C., Martínez‐Arán, A., Daban, C., Amann, B. L., Balanzá‐Martínez, V., Bonnín, C. D. M., Cruz, N., Franco, C., Tabarés‐Seisdedos, R., & Vieta, E. (2011) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2010.12.009 · Cited by 120
Cognitive Impairment in Patients with Bipolar Disorder: Impact of Pharmacological Treatment
Xu, N., Huggon, B., & Saunders, K. (2019) · CNS Drugs · doi:10.1007/s40263-019-00688-2 · Cited by 98
The Management of Cognitive Impairment in Bipolar Disorder: Current Status and Perspectives
Sanches, M., Bauer, I. E., Galvez, J. F., Zunta‐Soares, G. B., & Soares, J. C. (2014) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000120 · Cited by 86
“A randomized, double-blind crossover study using the second-generation antipsychotics risperidone and quetiapine in euthymic BD patients showed that quetiapine had adverse effects on psychomotor speed, attention, and working memory.(42) In a larger study on 119 euthymic BD patients, risperidone- and olanzapine-treated…”
BackgroundMyczkowski, M. L., Fernandes, A., Moreno, M., Valiengo, L., Lafer, B., Moreno, R. A., Padberg, F., Gattaz, W., & Brunoni, A. R. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.04.022 · Cited by 66
“For instance, anticonvulsant and antipsychotic drugs often lead to psychomotor retardation and memory decline (Gualtieri and Johnson, 2006; Harvey et al., 2007); whereas lithium effects are mixed, improving some cognitive domains while decreasing the performance in others (Malhi et al.”
BackgroundThe high prevalence of obstructive sleep apnea among patients with bipolar disorders
Kelly, T., Douglas, L., Denmark, L., Brasuell, G., & Lieberman, D. Z. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.05.047 · Cited by 57
Laskemoen, J. F., Büchmann, C. B., Barrett, E. A., Høegh, M. C., Haatveit, B. C., Vedal, T. S. J., Ueland, T., Melle, I. S., Aas, M., & Simonsen, C. (2019) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-019-01075-0 · Cited by 49
Temmingh, H. S., Williams, T., Siegfried, N., & Stein, D. J. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011057.pub2 · Cited by 76
Loebel, A. D., SIU, C. O., Cucchiaro, J. B., Pikalov, A. A., & Harvey, P. D. (2013) · CNS Spectrums · doi:10.1017/s1092852913000904 · Cited by 44
Self-citationBervoets, C., Morrens, M., Vansteelandt, K., Kok, F., de Patoul, A., Halkin, V., Pitsi, D., Constant, E., Peuskens, J., & Sabbe, B. (2012) · CNS Drugs · doi:10.1007/s40263-012-0003-4 · Cited by 44
Soeiro‐de‐Souza, M. G., Dias, V. V., Missio, G., Balanzá‐Martínez, V., Valiengo, L. D. C. L., Carvalho, A. F., & Moreno, R. A. (2015) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2015.2213 · Cited by 40
“In an RCT with a cross-over design, the acute effects of risperidone (2 mg) or quetiapine (200 mg) were assessed in patients with stable BD type I. Quetiapine was associated with more immediate adverse overall cognitive performance and sedation than risperidone (68).”
Rascati, K. L., Richards, K. M., Ott, C. A., Goddard, A. W., Stafkey-Mailey, D., Alvir, J. M., Sanders, K. N., & Mychaskiw, M. A. (2011) · Psychiatric Services · doi:10.1176/ps.62.9.pss6209_1032 · Cited by 38
Nikisch, G., Baumann, P., Wiedemann, G., Kießling, B., Weißer, H., Hertel, A., Yoshitake, T., Kehr, J., & Mathé, A. A. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181f2288e · Cited by 30
Quetiapine treatment and improved cognitive functioning in borderline personality disorder
den Eynde, F. V., Saedeleer, S. D., Naudts, K. H., Day, J. M., Vogels, C., Heeringen, C. V., & Audenaert, K. (2009) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1075 · Cited by 21
Gao, S., Hu, Z., Cheng, J. H., Zhou, W.-H., Xu, Y., Xie, S., Liu, S.-Y., Li, Z.-F., Guo, J., Dong, J., et al. (2012) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2012.04.016 · Cited by 22
“In line with previous reports [28,29], the risperidone treatment improved the cognition ofmost schizophrenics in this study (Table S2).”
ResultTorres, I., Solé, B., Corrales, M., Jiménez, E., Rotger, S., Serra-Pla, J., Forcada, I., Richarte, V., Mora, E., Jacas, C., et al. (2017) · Bipolar Disorders · doi:10.1111/bdi.12540 · Cited by 22
Joint Attention Virtual Classroom: A Preliminary Study
Seo, S.-H., Kim, E. J., Mundy, P. C., Heo, J., & Kim, K. K. (2019) · Psychiatry Investigation · doi:10.30773/pi.2019.02.08 · Cited by 19
Chen, X., Liu, H., Gan, J., Wang, X., Yu, G., Li, T., Liang, X., Yu, B., & Xiao, L. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00984 · Cited by 19
Definition and Measurement of Neurocognition and Social Cognition
Kern, R. S., & Horan, W. P. (2010) · Key issues in mental health (Online)/Key issues in mental health (Print) · doi:10.1159/000284375 · Cited by 26
Drug Class Review: Atypical Antipsychotic Drugs
McDonagh, M. S., Peterson, K., Carson, S., Fu, R., & Thakurta, S. (2010) · Cited by 16
Functional impairment in adult bipolar disorder with ADHD
Torres, I., Garriga, M., Solé, B., Bonnín, C. D. M., Corrales, M., Jiménez, E., Solé, E., Ramos‐Quiroga, J. A., Vieta, E., Goikolea, J. M., et al. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.09.037 · Cited by 18
Chen, W., Liu, H., Cheng, Y., Li, H., Huang, C., Ding, Y., Huang, M., Chiu, C., Tu, Y., & Kuo, P. (2021) · Clinical Epidemiology · doi:10.2147/clep.s335584 · Cited by 14
Antioxidative Effect of Quetiapine on Acute Ultraviolet-B-Induced Skin and HaCaT Cell Damage
Xu, P., Zhang, M., Wang, X., Yan, Y. C., Chen, Y., Wu, W., Zhang, L., & Zhang, L. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19040953 · Cited by 14
“Quetiapine improves schizophrenia symptoms, has sedative effects, and can be safely used with only relatively mild adverse events [8].”
BackgroundTortella, G., Sampaio-Júnior, B., Moreno, M., Moffa, A. H., da Silva, A. F., Lafer, B., Lotufo, P. A., Gattaz, W. F., Borrione, L., Machado‐Vieira, R., et al. (2020) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-020-01121-2 · Cited by 15
Arnautovska, U., Vitangcol, K. J., Kesby, J. P., Warren, N., Rossell, S. L., Neill, E., Harris, A. W. F., Galletly, C. A., Castle, D. J., & Siskind, D. J. (2023) · Schizophrenia Research Cognition · doi:10.1016/j.scog.2023.100283 · Cited by 8
“, 2013) and those with bipolar disorder (Harvey et al., 2007; Rakofsky et al., 2014).”
BackgroundGao, K., Su, M., Ganocy, S. J., Goto, T., Yuan, C., Fang, F., Conroy, C. M., Brownrigg, B., Serrano, M. B., & Calabrese, J. R. (2019) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001031 · Cited by 7
Streicher, J., Wen, H., Blom, T. J., Tallman, M. J., Strawn, J. R., Klein, C. C., Patino, L. R., & DelBello, M. P. (2020) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2019.0169 · Cited by 6
“One study found that in patients with bipolar disorder, initiation with quetiapine was associated with impaired processing speed and attention relative to risperidone, as well as more somnolence (Harvey et al. 2007).”
BackgroundSerum levels of olanzapine are associated with acute cognitive effects in bipolar disorder
Shoshina, I. I., de Almeida, N. L. P., de Oliveira, M. E. C., Trombetta, B. D. N. T., Silva, G. M., Fars, J., dos Santos, N. A., & Fernandes, T. P. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114443 · Cited by 8
Zou, T., Yang, M., Chen, Z., Xie, H., Huang, J., Qin, Y., Liu, F., Chen, H., Xu, X., Chen, J., et al. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-05831-y · Cited by 5
“Other drugs such as ris-peridone and quetiapine may cause side effects such as drowsiness, which may also be confused with BD-related neurocognitive deficits [32, 33].”
BackgroundRehabilitación de funciones ejecutivas tras lesión cerebral.
Arango‐Lasprilla, J. C., & Parra, M. A. (2008) · Revista Neuropsicología, Neuropsiquiatría y Neurociencias · Cited by 4
Zack, M. H., Lobo, D. S. S., Biback, C., Fang, T., Smart, K. A., Tatone, D., Kalia, A., DiGiacomo, D. V., & Kennedy, J. L. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119855972 · Cited by 4
Abdelmissih, S., Hosny, S. A., Elwi, H. M., Sayed, W. M., Eshra, M. A., Shaker, O. G., & Samir, N. F. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06619-4 · Cited by 3
“Among atypical antipsychotics, quetiapine (QUET), another sleep aid, triggers cognitive impairment in patients with dementia and bipolar disorder (Ballard et al. 2005; Harvey et al. 2007).”
BackgroundLurasidone Effects on Cognition and Functional Capacity in Schizophrenia
Harvey, P. D., Ogasa, M., SIU, C. O., & Loebel, A. D. (2016) · Clinical Neuropsychopharmacology and Therapeutics · doi:10.5234/cnpt.7.11 · Cited by 1
Self-citationOsborne, V., Davies, M., Evans, A., & Shakir, S. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320954616 · Cited by 1
Huỳnh, C. (2008) · doi:10.71781/29448 · Cited by 1
The impact of different estimation procedures on net monetary benefit in clinical trials
Engelhart, L. (2008) · doi:10.7282/t3df6r5x
Self-citationEffects of central nervous system depressant drug overdose on cognitive functions and driving
Dassanayake, W. D. M. T. L. (2012) · Figshare
Kałwa, A., Piróg-Balcerzak, A., & Święcicki, Ł. (2013) · Archives of Psychiatry and Psychotherapy · doi:10.12740/app/17268
“The most robust cognitive deficits, particularly impairment of working memory and executive functions, are considered to be associated with antipsychotic pharmacological treatments [11, 12].”
Backgroundde Souza, G. T. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2019.tde-16102019-151043
Sono e ritmos circadianos na depressão resistente
Filho, D. Z. (2014) · Debates em Psiquiatria · doi:10.25118/2763-9037.2014.v4.240
Current awareness: Pharmacoepidemiology and drug safety
John Wiley & Sons, L. (2008) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1485
Brown, J. A. (2012) · UC Research Repository (University of Canterbury) · doi:10.26021/7156
Zou, T., Yang, M., Chen, Z., Xie, H., Huang, J., Qin, Y., Liu, F., Chen, H., Xu, X., Chen, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25876093
Metadata
- Authors
- Harvey, P. D., Hassman, H., Mao, L., Gharabawi, G. M., Mahmoud, R. A., & Engelhart, L. M.
- Affiliations
- Icahn School of Medicine at Mount Sinai (US)
- Johnson & Johnson (United States) (US)
- F. Hoffmann-La Roche AG (CH)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2007-08-15
- Volume
- 68
- Issue
- 08
- Pages
- 1186-1194
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2162421896
- Cited by
- 52
- References
- 47
- Citations by year
- 2024: 3 · 2023: 1 · 2022: 1 · 2021: 1 · 2020: 4 · 2019: 6 · 2018: 3 · 2017: 3 · 2016: 1 · 2015: 2 · 2014: 2 · 2013: 5 · 2012: 5
- FWCI
- 2.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- risperidone, quetiapine, bipolar I disorder, cognitive function, attention, working memory, executive function, processing speed, sleepiness, fatigue
- MeSH terms
- Quetiapine Fumarate, Adult, Attention, Bipolar Disorder, Cognition, Cognition Disorders, Dibenzothiazepines, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Male, Memory, Middle Aged, Reaction Time, Sleep Wake Disorders, Sleep Stages, Antipsychotic Agents, Risperidone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.